Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DCTH 
Delcath Systems Inc (DCTH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: DCTH (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $22.3
1 Year Target Price $22.3
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 117.72% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 341.13M USD | Price to earnings Ratio 322 | 1Y Target Price 22.3 |
Price to earnings Ratio 322 | 1Y Target Price 22.3 | ||
Volume (30-day avg) 6 | Beta 0.41 | 52 Weeks Range 8.12 - 18.23 | Updated Date 12/4/2025 |
52 Weeks Range 8.12 - 18.23 | Updated Date 12/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.03 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-04 | When - | Estimate -0.03 | Actual 0.02 |
Profitability
Profit Margin 1.51% | Operating Margin (TTM) -1.89% |
Management Effectiveness
Return on Assets (TTM) 4.72% | Return on Equity (TTM) 1.94% |
Valuation
Trailing PE 322 | Forward PE 14.18 | Enterprise Value 250358418 | Price to Sales(TTM) 4.29 |
Enterprise Value 250358418 | Price to Sales(TTM) 4.29 | ||
Enterprise Value to Revenue 3.15 | Enterprise Value to EBITDA 40.43 | Shares Outstanding 35313718 | Shares Floating 34345416 |
Shares Outstanding 35313718 | Shares Floating 34345416 | ||
Percent Insiders 2.73 | Percent Institutions 51.06 |
Upturn AI SWOT
Delcath Systems Inc
Company Overview
History and Background
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of rare cancers. Founded in 1988, the company has focused on developing and commercializing its CHEMOSAT Delivery System for the treatment of liver cancers.
Core Business Areas
- Chemosat Delivery System: This segment focuses on the Chemosat Delivery System for the treatment of unresectable hepatic malignancies. Chemosat delivers chemotherapy directly to the liver while controlling systemic exposure.
Leadership and Structure
Information is limited, but Delcath operates with a CEO, CFO and board of directors overseeing operations.
Top Products and Market Share
Key Offerings
- Chemosat Delivery System: Chemosat is Delcath's primary product. It is used to treat unresectable hepatic metastases from ocular melanoma (OM) and other cancers. Market share data is limited; Delcath focuses on a niche market within liver cancer treatment. Competitors include traditional systemic chemotherapy, Y90 radioembolization, and surgical resection.
Market Dynamics
Industry Overview
The industry involves interventional oncology, focusing on targeted drug delivery for liver cancers. It's a growing market driven by the need for more effective and less toxic cancer treatments.
Positioning
Delcath is positioned as a specialist in percutaneous hepatic perfusion (PHP) therapy for liver metastases. They aim to provide a treatment option for patients who have failed other therapies.
Total Addressable Market (TAM)
The estimated TAM for liver cancer treatments is in the billions of dollars. Delcath's TAM is limited to the specific subset of patients suitable for PHP, which is significantly smaller, but growing. They are well positioned for their TAM.
Upturn SWOT Analysis
Strengths
- Chemosat Delivery System
- Targeted drug delivery
- Treatment option for difficult-to-treat liver metastases
- Orphan Drug Designation
Weaknesses
- Limited market size
- High cost of treatment
- Regulatory hurdles
- Dependence on a single product
Opportunities
- Expanding indications for Chemosat
- Partnering with other pharmaceutical companies
- Developing new drug delivery technologies
- Market expansion to other countries
Threats
- Competition from other cancer treatments
- Reimbursement challenges
- Adverse events
- Changing regulatory landscape
Competitors and Market Share
Key Competitors
- MRK
- BMY
- GILD
Competitive Landscape
Delcath has a niche product but faces competition from larger pharmaceutical companies with broader cancer treatment portfolios. Delcath's advantage lies in its targeted drug delivery technology.
Growth Trajectory and Initiatives
Historical Growth: Growth has been dependent on Chemosat adoption and regulatory approvals in various markets.
Future Projections: Analyst projections vary but generally suggest revenue growth driven by increased Chemosat use. This depends on regulatory approvals and market penetration.
Recent Initiatives: Delcath continues to seek regulatory approvals for Chemosat in new markets and for new indications.
Summary
Delcath Systems Inc. is a niche player in the interventional oncology space with its Chemosat Delivery System. It addresses a specific subset of liver cancer patients, which is both a strength and a weakness due to the limited market. Growth depends on expanding indications and regulatory approvals. The company should focus on partnerships to enhance its market reach and product portfolio.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Databases
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is estimated and may not be precise. Financial data and other information are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Delcath Systems Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2018-05-29 | CEO & Director Mr. Gerard J. Michel MBA, MS | ||
Sector Healthcare | Industry Medical Devices | Full time employees 96 | Website https://www.delcath.com |
Full time employees 96 | Website https://www.delcath.com | ||
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1987 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.